title: Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients.
abstract: Aberrant Rad51 expression is implicated in the progression of human malignancies. However, the role of Rad51 in colorectal cancer (CRC) remains undefined. This study aimed to establish a relationship between Rad51 and clinicopathologic features of CRC.
  
  
  
  We retrospectively examined the paraffin-embedded tissue samples obtained from 54 patients with CRC who had received surgical therapies at our institution during 2006-2008. Rad51 expression in adenocarcinoma, paracancerous tissue, and normal colonic tissue was determined by immunohistochemistry. The correlation between Rad51 immunoreactivity and clinicopathologic features of these patients was evaluated.
  
  
  
  Rad51 immunoreactivity was detected in 67% of adenocarcinoma, 48% of paracancerous tissue, and 27% of normal colonic mucosa. Rad51 expression in adenocarcinoma was significantly higher than normal colonic tissue (p < 0.05). Rad51 was also overexpressed in poorly differentiated tumors and tumor samples from patients with lymph node metastasis (p < 0.05). Patients with Rad51 overexpression had a 69% two-year survival, 49% three-year survival, and 16% five-year survival, considerably worse than patients with negative Rad51 expression (p < 0.05).
  
  
  
  Our data suggest that Rad51 overexpression is correlated with malignant phenotypes of CRC and may predict poor prognosis for these patients.
authors.affiliation: Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Wei-Ya
authors.initials: WY
authors.lastname: Wang
authors.affiliation: Center for Radiation Physics and Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Jiang-Hong
authors.initials: JH
authors.lastname: Xiao
authors.affiliation: Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.affiliation: Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Dian-Ying
authors.initials: DY
authors.lastname: Liao
authors.affiliation: Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.affiliation: Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Luo
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D003106:Colon / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D004249:DNA Damage / Q000235:genetics; D004260:DNA Repair / Q000235:genetics; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D051135:Rad51 Recombinase / Q000235:genetics / Q000378:metabolism*; D012189:Retrospective Studies; D016610:Tissue Embedding
chemical_list: D014408:Biomarkers, Tumor; C495153:RAD51 protein, human; D051135:Rad51 Recombinase